IMMX
IMMX
US45258H1068
Immix Biopharma, Inc.
Loading chart...

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Latest News

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
IMMX
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
IMMX
IMMX
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
IMMX
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
IMMXBAC
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
IMMX

Related stocks

SGP
SGP • United States
SpyGlass Pharma, Inc.
24.92 USD
833.52M USD
TBPH
TBPH • United States
Theravance Biopharma, Inc.
17.03 USD
884.18M USD
JBIO
JBIO • United States
Jade Biosciences, Inc.
14.39 USD
915.17M USD 1Y +55.8%
ODTX
ODTX • United States
Odyssey Therapeutics, Inc.
19 USD
913.11M USD
SPTX
SPTX • United States
Seaport Therapeutics, Inc.
18.15 USD
971.58M USD
AKTS
AKTS • United States
Aktis Oncology, Inc.
18.15 USD
1.01B USD
VSTM
VSTM • United States
Verastem, Inc.
8.38 USD
758.92M USD 1Y -9.3%
SVRA
SVRA • United States
Savara, Inc.
4.92 USD
1.01B USD 1Y +39.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics
Country
United States
Region
North America
Sector
Healthcare
Industry
Biotechnology
Website
https://www.immixbio.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
107.3% p.a.
Max Drawdown (5Y)
-88.9%
Sharpe Ratio (5Y)
0.17
Beta Factor
0.24
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (107.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -88.9% in the extended horizon.
ende